Tag Archives: EU

European Pharma Policy Reaches "New Level of Timidity"

By Peter O’ Donnell, Applied Clinical Trials. The European Union has managed to snatch defeat from the jaws of opportunity once more! A long-heralded document portentously entitled “Pharmaceutical industry: a strategic sector for the European economy,” and supposedly initiating a new start in long-term thinking about boosting the drug industry, squeezes the thinnest and weakest […]
Posted in Europe, Guest Blog, Op-Ed, Regulatory | Also tagged , | Leave a comment

Eight Lessons for Enhancing Compliance Effectiveness in Europe

Andy Bender and Geert van Gansewinkel outline eight lessons for executing a soft change program for enhancing compliance effectiveness within European life sciences organizations. The European compliance and transparency landscape has changed rapidly over the last couple of years. Over and above the challenging compliance landscape, there is additional complexity impacting transparency relating to the […]
Posted in compliance, Europe, Global, Guest Blog | Also tagged , , | Leave a comment

Desperate Measures: Industry Teams with Parallel Traders to Tackle Counterfeiters in Europe

While action is heating up at the international level to tackle counterfeit drugs, Europe is making its own efforts to stop fake medicines from entering the legal supply chain. An improbable cross-sector partnership is struggling to secure support for a pan-European system to keep counterfeits out. It’s improbable because it brings together not only manufacturers, […]
Posted in Anti-counterfeiting, Europe, Global, Guest Blog, Regulatory, Safety | Also tagged , , , , , | Leave a comment

EMA to Review Safety of Ibuprofen Medicines

The European Medicine Agency’s Pharmacovigilance and Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen medicines.
Posted in Europe, Global, Regulatory, Safety | Also tagged , , , , | Leave a comment

EU Steps Up Manufacturing Inspection Efforts

One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”. The European Directorate for the Quality of Medicines & Healthcare, which is responsible for the European Pharmacopoeia but also runs its own inspection operations, has been tightening […]
Posted in Europe, Guest Blog, Manufacturing, Regulatory | Also tagged , , , | Leave a comment
  • Categories

  • Meta